Isavuconazole use and TDM in real-world pediatric practice.

Berta Fernández Ledesma Natalia Mendoza-PalomarSusana Melendo PérezAurora Fernández-PoloBerta Renedo MiróAlba Pau ParraSonia Luque PardosSantiago Grau CerratoJaume Vima BofarullMaría Teresa Martín-GómezMontserrat Pujol JoverMaria Isabel Benítez-CarbanteCristina Díaz de HerediaPere Soler-Palacin

Published in: Antimicrobial agents and chemotherapy (2023)

Isavuconazole (ISA) is approved for treating invasive aspergillosis and mucormycosis in adults, but its use in children remains off-label. We report on the use of ISA in real-world pediatric practice with 15 patients receiving ISA for treatment of invasive fungal infections. Therapeutic drug monitoring (TDM) was performed in all patients, with 52/111 (46.8%) C trough determinations out of range, thus supporting the need for TDM in children, especially those receiving extracorporeal membrane oxygenation (ECMO).

Keyphrases

extracorporeal membrane oxygenation
acute respiratory distress syndrome
respiratory failure
young adults
primary care
healthcare
mechanical ventilation
quality improvement
intensive care unit
combination therapy
smoking cessation